Study shows that it’s okay to mix different covid-19 vaccines.

Since the use of the Oxford-AstraZeneca vector vaccine against COVID-19 has been discontinued in people under the age of 65, all people who had already received their first dose of this vaccine were recommended for the vaccine. second.

During an average follow-up of 2.5 months after the second test, the study showed a 67% lower risk of infection with a combination of Oxford-AstraZeneca + Pfizer-BioNTech, and a lower risk of 79% with Oxford / AstraZeneca + Moderna, both compared to non-vaccinated people. For people who received two doses of the Oxford-AstraZeneca vaccine, the risk reduction was 50%. These risk estimates were considered after accounting for differences in vaccine date, participants’ age, economic status, and other risk factors for COVID-19. It is important to note that the efficacy estimates apply to various Delta infections, which dominated the confirmed cases during the follow-up period. There were very low incidence of adverse events for all vaccination schedules. The number of cases of COVID-19 cases severe enough to cause hospitalization was too low for researchers to calculate the effectiveness against this discovery.

Previous research has shown that mixed vaccination schedules provide a consistent immune response. However, it is unclear to what extent these programs could reduce the risk of clinical infection. This is a knowledge gap that a new study by Umea researchers aimed to fill. The study is based on data from the Swedish Register of the Swedish Public Health Agency, the Swedish National Health and Welfare Board and Statistics. In the main analysis, about 700,000 people were included.

“The results of the study could be significant for vaccination strategies in different countries,” explains Marcel Ballin, a doctoral candidate in medical medicine at Umea University and co-author of the study. “The World Health Organization has stated that despite the promising results of previous studies on immune response to mixed vaccines, there is a need for more studies to assess their safety and efficacy against clinical outcomes. We now have similar research.”

sambazanews@gmail.com